Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.

导出 LinkOut

翻译打印收藏纠错

作者： Wenhao,Xu ; Aihetaimujiang,Anwaier ; Wangrui,Liu ; Gaomeng,Wei ; Jiaqi,Su ; Xi,Tian ; Jing,Xia ; Yuanyuan,Qu ; Jianyuan,Zhao ; Hailiang,Zhang ; Dingwei,Ye

关键词 CDKN2A MTAP genomic alteration immunotherapy renal cell carcinoma sarcomatoid differentiation tumor microenvironment

主题词癌, 肾细胞(Carcinoma, Renal Cell);周期素依赖激酶抑制剂p16(Cyclin-Dependent Kinase Inhibitor p16);基因组学(Genomics);人类(Humans);肾肿瘤(Kidney Neoplasms);预后(Prognosis);蛋白质精氨酸N-甲基转移酶(Protein-Arginine N-Methyltransferases)

DOI 10.3389/fimmu.2022.953721

PMID 35979371

发布时间 2024-09-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in immunology

2022年13卷

953721页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.

Frontiers in immunology

相似文献

Frontiers in immunology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.

Frontiers in immunology

相似文献

Frontiers in immunology

相关期刊

检索历史清除